The conference will start on Sunday, September 24 with a series of educational workshops. Please note that space is limited to 23 persons per workshop and registration is on first-come, first-served basis.
To secure your participation, simply purchase the workshops package during the registration process. That package will grant you access to two workshops (one at 13:30 and a second one at 16:30) for 89 euros.
Please note that if you intend to participate to only one workshop, the price remains the same.
Session 1: 13:30 – 16:00
Workshop A: TRANSLATING BIOMARKERS INTO IN-VITRO DIAGNOSTICS (IVD)
The workshop will provide an overview of all the steps starting from biomarker(s) discovery to product marketing and reimbursement.
Using real life case studies, the participants will experience potential roadblocks researchers need to tackle together with the various development phases to launch successfully an IVD on the market.
Speakers: Alain van Gool (Radboudumc, NL), Paul Docherty (Hologic, UK), Monica Marchese (IBBL, LU) and Jiri Drabek (IMTM, CZ)
Workshop B: Challenges and best practices in academic drug development
During this workshop you will gain an understanding of the do’s and don’ts in academic drug research. Based on real life case studies we will zoom in on key components for success, root causes for failure, and main struggles for ongoing projects. Participants will be encouraged to share their own experiences in drug discovery and development with the audience and the panel, with an emphasis on novel approaches and emerging technologies.
Speakers: Marian Hajduch (IMTM, CZ), Mario Salmona (Mario Negri Institute, IT), Alfredo Budillon (Istituto Tumori Napoli G. Pascale, IT) and Irena Mlinarič-Raščan (University of Ljubljana, SI)
Topics case studies: Trabectedin, Peptidomimetics, Transferrin conjugated nanoparticles & In Silico Approach
Workshop C: Designing your research for maximum impact: building a data package fit for investment
In this workshop, you will learn what types and level of research data you will need to secure interest from the investors and shared risk collaborators that finance early development projects, so you can structure (or assess, if you are a funder) your research for maximum future potential. On the basis of examples and use cases, learn about the most common pitfalls and the recipes for successful further funding of your positive results.
Speakers: Justin Bryans and Mike Dalrymple (MRC Technology, UK), James McArthur (Cydan Development Inc, US)
Coffee break: 16:00 – 16:30
Session 2: 16:30 – 19:00
WORKSHOP D: POTENCY ASSAYS IN ATMP’S AND VACCINES
This workshop will address the issue of the Potency Assay, highlighting the strategy, pitfalls and regulatory pathway for the development of ATMPs and Vaccines
Speakers: Keynotes by Koen Brusselmans (Scientific Institute of Public Health, BE), Marcus Timon (Spanish Agency of Medicinal Products, E), Ivana Haunerova (State Institute for Drug Control, CZ) and Graziella Pellegrini (Unimore, IT)
Chaired by Maria Cristina Galli (Istituto Superiore di Sanità, IT) and Lucia Gabriele (Istituto Superiore di Sanità, IT)
WORKSHOP E: MOLECULAR IMAGING SUPPORTING CNS DRUG DEVELOPMENT
The added value of imaging as a non-invasive diagnostic technique in neurology is a ’no-brainer’. At the same time the development of novel therapies faces challenges due to the extremely high failure rates in development of novel effective drugs (e.g. against neurodegenerative disease). Using several neuroimaging case studies, we will discuss the challenges, opportunities and lessons learnt for how molecular imaging can support the development of novel CNS drugs.
Speakers: Bert Windhorst (VUMC, NL), Tonny Gee (King’s college London, UK) in joint collaboration with the EANM Drug Development Committee, ESMI Neuroimaging Working Group and industry representatives
WORKSHOP F: DESIGNING YOUR RESEARCH FOR MAXIMUM IMPACT – HOW TO ASSESS AND MAXIMISE THE POTENTIAL IMPACT OF YOUR RESEARCH PLAN
This session will provide an overview of the main components of the development pipeline that affect the feasibility of translational research. By being aware of the major issues, including definition of the end-product and regulatory classification, target patient population, intellectual property, market structure and pipeline, you will have more confidence in designing or selecting your projects for maximum potential impact.
Speakers: Anton Ussi (EATRIS), Tim Moser (EATRIS) and Giovanni Miagliaccio (EATRIS)
Questions? Please contact Rosan Vegter, EATRIS Training Manager: email@example.com